| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919) |
| Indication |
Used for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state. |
| Pharmacology |
Thiamylal, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia. |
| Toxicity |
Intravenous LD50 in rat is 51 mg/kg. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. |
| Absorption |
Rapidly absorbed (high lipid solubility). |
| Half Life |
Although no studies have been performed on humans, the half-life in cats is 14.3 hours. |
| External Links |
|
|